User contributions for DorotheaSigel

A user with 2 edits. Account created on 15 November 2024.
Jump to navigation Jump to search
Search for contributionsExpandCollapse
⧼contribs-top⧽
⧼contribs-date⧽

15 November 2024

  • 18:5418:54, 15 November 2024 diff hist +6,187 N What Physicians Want Clients Knew About Anti-obesity Medicine American Medical AssociationCreated page with "[https://doi.org/10.1038/s41573-021-00337-8 doi.org]The higher 1 mg dosage provides higher fat burning but additionally enhances the danger of damaging cardio results. Weight management observed in tests of PHN/TPM appears to be above weight management reported in lorcaserin trials and in several of the trials of bupropion/naltrexone. In three big (roughly 8,000 people) lorcaserin RCTs of 52-- 104 weeks duration, fat burning was 3.0-- 3.7% versus placebo when combined wi..." current
  • 18:5418:54, 15 November 2024 diff hist +8,867 N User:DorotheaSigelCreated page with "A vital transporter answerable for kidney glucose reabsorption, dapagliflozin is a strong, extremely selective and by mouth energetic suppressor of the human kidney sodium glucose cotransporter type 2 (SGLT2) [92] A medical trial of dapagliflozin in pediatric people aged 10-- 17 years for the therapy of type 2 diabetes mellitus has actually been performed, however professional tests of this drug for pediatric or young adult weight problems is not defined [94] In clinical..." current